We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Thrombolytics Are Not Contraindicated in the Very Old

Stephen W. Smith, MD
Arch Intern Med. 2002;162(18):2139-2140. doi:.
Text Size: A A A
Published online


The article by Soumerai et al1 regarding the effectiveness of thrombolytic therapy in the elderly was an interesting and important analysis, but, similar to Thiemann et al2 in their article questioning the use of thrombolytics in the elderly, they start with the premise that the data of the Fibrinolytic Therapy Trialists' (FTT) Collaborative Group3 (combined data from 9 placebo-controlled thrombolytic trials involving at least 1000 patients) demonstrated only minimal benefit for those older than 75 years. In fact, in the latter study, the data for the elderly was terribly misrepresented because only 5 of the 9 studies (GISSI-1 [Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto Miocardio],4 ISIS-2 [Second International Study of Infarct Survival Collaborative Group],5 ISIS-3 [Third International Study of Infarct Survival Collaborative Study Group],6 EMERAS [Estudio Multicentro Estreptoquinsa Republicas de America del Sur],7 and LATE [Late Assessment of Thrombolytic Efficacy Study Group]8) included significant numbers of elderly patients, and there were major problems with the latter 3.68 GISSI-1 and ISIS-2 showed highly significant benefit for the elderly even though they included many patients who presented more than 6 hours after symptom onset. ISIS-3, EMERAS, and LATE inappropriately diluted this positive data: ISIS-3 compared the use of thrombolytics with placebo only in patients whose indication for thrombolytic therapy was unclear, whether because presentation was more than 6 hours after symptom onset or because of lack of ST elevation. EMERAS and LATE included only patients with 6 to 24 hours of symptoms, and ST elevation was not required for entry. According to White,9 the FTT data for the elderly were recently reanalyzed by the FTT secretariat. Approximately 3300 patients older than 75 years who presented within 12 hours of symptom onset and with either ST elevation or bundle branch block were randomized to treatment with a thrombolytic or placebo; 35-day mortality was reduced from 29.4% to 26.0% (P = .03), or 34 lives saved per 1000 treated. This absolute mortality reduction is as great as that for any other group. To my knowledge, the data referred to by Dr White have not been published. Their publication would be of great value in this debate, and would provide the best evidence possible that thrombolytic therapy should not be withheld on the basis of age alone.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Solitaire stentectomy: 'deploy and engage' and 'loop and snare' techniques. J Neurointerv Surg Published online Aug 18, 2016;
From Acute to Chronic Thromboembolic Disease. Ann Am Thorac Soc 2016;13 Suppl 3():S207-14.

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
Developing Grade Recommendations

Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
From Evidence to Recommendations